In Vivo System Articles & Analysis
11 news found
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has recently launched its new line of PLGA-based drug delivery systems for in vitro and in vivo applications, including biocompatible and biodegradable PLGA nanoparticles with different surface modifications (e.g., COOH groups, methoxy PEG, and PEG-azide). In recent years, ...
Three patients have at least 12 months of follow-up, and all remain in morphological complete remission (CR); two patients have remained progression-free for more than two years (26.5 months and 24.2 months) and a third for more than one year (12.5 months) post-transplant at the time of abstract submission. Immune system reconstitution through the first 100 days post-treatment ...
Agreement strengthens Bayer’s new cell and gene therapy platform further Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement Bayer AG and Mammoth Biosciences, Inc., which is ...
Despite multiple cytogenetic abnormalities and a high risk of relapse, these patients remain in remission 26.5, 24.2 and 12.5 months post-transplant, respectively. Immune system reconstitution at six months post-treatment demonstrates continued normal function including observed elevations in T cells, B cells, and gamma-delta T cells. ...
Biocompatibility assessment is an essential part of the overall safety evaluation of medical devices. Biocompatibility systemic toxicity tests are in vivo systemic tests used to assess systemic damage or activation of a system, not damage to individual cells or organs. Systemic toxicity tests ...
BySTEMart
However, the clinical utility of IL12 has been limited by toxicities stemming from systemic cytokine exposure. Harnessing the power of IL12 in a therapeutic setting will require technologies that provide tight control of IL12 expression and localization. In mouse models, Obsidian demonstrates that membrane-bound IL12 (mbIL12) increases activity at the tumor site in ...
Kawahara was a member of the founding management team and Corporate Director, Planning and Business Development, for Xenogen Corporation (Alameda, CA), developed IVIS® in vivo biophotonic imaging system, and held positions of increasing responsibility at Becton Dickinson and Company (San Jose, CA) including Director, Reagents and Applications Development, for ...
“We believe our novel ultra-small CRISPR systems have the potential to be game changers when it comes to systemic and targeted delivery of in vivo gene-editing therapies,” said Peter Nell, Chief Business Officer and Head of Therapeutic Strategy at Mammoth Biosciences. ...
The selected ADCs will be evaluated on its anti-tumour activity in in vitro and in vivo systems and will then be considered for IND-enabling studies. The parties hope to leverage IntoCell's validated linker system and novel payloads with Ab Studio's antibodies with enhanced and optimised internalisation properties. "We are excited to start a new ...
The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics. ...
He has dedicated the last 22 years to researching and developing novel therapeutic systems and devices, based on the generation and control of electromagnetic energy at a range of frequencies, to successfully address a number of unmet clinical needs. ...